Profectus BioSciences develops vaccines and antibody therapeutics, including an antibody candidate m102.4 intended as a post-exposure prophylactic against Nipah and Hendra viruses. The company received a $5.4M grant to support preclinical development of m102.4. Profectus is collaborating with Dr. Christopher Broder (USU) and Dr. Thomas Geisbert (Galveston National Laboratory, University of Texas Medical Branch) on the program. It is partnering with Catalent Pharma Solutions to use GPEx® technology to produce high-yield mammalian cell lines for cGMP production of m102.4. The company’s pipeline and focus include chronic viral diseases such as HCV, HPV, HSV-2, HIV, as well as malaria, Ebola and Marburg viruses. Profectus was established in 2003 and is based in Baltimore, MD. Profectus Biosciences is a technology-based vaccine company devoted to the treatment and prevention of chronic viral diseases, aiming to reduce morbidity and mortality. Its proof-of-concept target is human immunodeficiency virus (HIV), with an intermediate-term focus on hepatitis C virus (HCV). The company advances vaccine technologies for patients suffering from chronic viral infections. The firm's founding mission reflects a "bench-top-to-bedside" approach driven by co-founders Drs. Gallo, Blattner, and Redfield. In 1996 the founders were recruited to the University of Maryland Biotechnology Institute to create the Institute of Human Virology. Per SEC filings, the company completed a $6.79 million offering from a single investor.

Total raised

$12M

Funding rounds

2

Latest round

Grant

Latest activity

Dec 2011